Go online to PeerView.com/BNB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert on homozygous familial hypercholesterolemia (HoFH) discusses the latest data for novel lipid-lowering therapies and offers strategies for individualizing treatment regimens to improve outcomes for patients with HoFH. Upon completion of this activity, participants should be better able to: Apply standards of care to initiate and escalate lipid-lowering therapies in patients with HoFH; Distinguish the therapeutic characteristics of recently approved HoFH therapies according to their mechanisms of action; and Evaluate the benefits and limitations of approved HoFH therapies to individualize patient care.

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.  Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported through an educational grant from Bristol Myers Squibb.  Disclosure information is available at the beginning of the video presentation.

Milind Desai, MD, MBA, FACC, FAHA, FESC, Andrew Willeford, PharmD, PhD, BCCP - Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.  Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals   In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Merck & Co., Inc.  Disclosure information is available at the beginning of the video presentation.

Lecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.  Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Novo Nordisk Inc.  Disclosure information is available at the beginning of the video presentation.

A. Michael Lincoff, MD - Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.  The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an independent educational grant from AstraZeneca.  Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.  Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.  Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.  Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.  Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.  Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.  Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.  Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.  Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.  Faculty/PlannerJared Weiss, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.  Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH

Download our free app to listen on your phone